Boston Scientific Q4 Earnings Disappoint, Shares Plummet 16% Despite Solid Growth
ByAinvest
Friday, Feb 6, 2026 1:17 am ET1min read
BSX--
Boston Scientific's Q4 earnings beat expectations, with 16% sales and 14% EPS growth. However, the company missed Q1 and 2026 guidance by a penny, causing a 16% stock price drop. Despite this, the company delivered 18% sales growth in its cardiovascular segment and 12% in its medsurg unit, with a projected 11.25% sales growth in 2026. The stock is trading at 28 times forward FCF and has a history of innovation and investment.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet